ישראל - עברית - Ministry of Health

sanofi israel ltd - amiodarone hydrochloride - תמיסה להזרקה - amiodarone hydrochloride 50 mg / 1 ml - amiodarone - amiodarone - corronary insufficiency, arrhythmias resistant to other treatments, wolf parkinson white syndrome.

ישראל - עברית - Ministry of Health

sanofi israel ltd - enoxaparin sodium - תמיסה להזרקה - enoxaparin sodium 100 mg/ml ml - enoxaparin - enoxaparin - enoxaparin sodium is an anti-coagulant. at dosesof 20 mg and 40 mg it is indicated for: - prophylactic treatment of thrombo-embolic disorders of venous origin and in particular in orthopedic surgery or in general surgery. - prevention of thrombus formation in the extra-corporeal circulation during hemodialysis. at dosege of 40 mg the indications are: - prophylactic treatment of deep vein thrombosis in patients who are bedridden due to an acute medial disorder: - heart failure (hyha class iii or iv) - acute respiratory failure - episode of acute infection or acute rheumatic disorder combined with at least one other venous thromboembolic risk factor. at high doses of 60, 80 ,100 mg clexan is indicated for: -treatment of deep vein thrombosis (dvt). - treatment of unstable angina and non-q-wave myocardial infaction administered concurrently with aspirin. - treatment of pulmonary embolism.treatment of acute st- segment elevation myocardial infarction, in combination with a thrombolytic agent in patients eligible o

ישראל - עברית - Ministry of Health

sanofi israel ltd - clopidogrel as hydrogen sulfate - טבליות מצופות פילם - clopidogrel as hydrogen sulfate 75 mg - clopidogrel - clopidogrel - prevention of atherotrobmotic eventsclopidogrel is indicated in :• adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.• adult patients suffering from acute coronary syndrome- non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave myocardial infarction (mi)), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapyprevention of atherotrobmotic and thromboembolic events in atrial fibrillation: in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for the treatment with vitamin k antagonists (vka) anti-thrombin or anti factor xa, and who have a low bleeding risk, clopid

ישראל - עברית - Ministry of Health

sanofi - aventis israel ltd - clopidogrel as hydrogen sulfate 300 mg - film coated tablets - clopidogrel - prevention of atherotrobmotic eventsclopidogrel is indicated in :• adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.• adult patients suffering from acute coronary syndrome- non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave myocardial infarction (mi)), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapyprevention of atherotrobmotic and thromboembolic events in atrial fibrillation: in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for the treatment with vitamin k antagonists (vka) anti-thrombin or anti factor xa, and who have a low bleeding risk, clopid

ישראל - עברית - Ministry of Health

sanofi israel ltd - dronedarone - טבליות מצופות פילם - dronedarone 400 mg - dronedarone - dronedarone - multaq is indicated for the maintenance of sinus rhythm after successful cardioversion in adult clinically stable patients with paroxysmal or persistent atrial fibrillation (af). due to its safety profile, multaq should only be prescribed after alternative treatment options have been considered.multaq should not be given to patients with left ventricular systolic dysfunction or to patients with current or previous episodes of heart failure.

ישראל - עברית - Ministry of Health

sanofi israel ltd - alfuzosin hydrochloride - טבליות עם שחרור מושהה - alfuzosin hydrochloride 5 mg - alfuzosin - alfuzosin - treatment of certain functional symptoms of benign prostatic hypertrophy, particularly if surgery has to be delayed for some reason

ישראל - עברית - Ministry of Health

sanofi israel ltd - alfuzosin hydrochloride - טבליות בשחרור ממושך - alfuzosin hydrochloride 10 mg - alfuzosin - alfuzosin - treatment of certain functional symptoms of benign prostatic hypertrophy particularly if surgery has to be delayed for some reason. adjuvant treatment to a catheter in acute urinary retention related to benign prostatic hypertrophy.

ישראל - עברית - Ministry of Health

sanofi - aventis israel ltd - ofloxacin 200 mg - film coated tablets - ofloxacin - for the treatment of bacterial infections if these are due to ofloxacin sensitive pathogens.

ישראל - עברית - Ministry of Health

sanofi israel ltd - levofloxacin as hemihydrate - טבליות מצופות פילם - levofloxacin as hemihydrate 500 mg - levofloxacin - levofloxacin - in adults with infections of mild to moderate severity tavanic tablets are indicated for the treatment of the following infections when due to levofloxacin - susceptible micro-organisms: acute sinusitis, acute exacerbation of chronic bronchitis, community-acquired pneumonia, complicated urinary tract infections including pyelonephritis, skin and soft tissue infections.

ישראל - עברית - Ministry of Health

sanofi - aventis israel ltd - lenograstim 33.6 miu/ml - lyophilized powder for injection - lenograstim - - reduction in duration of neutropenia and associated complications in patients undergoing bone marrow transplantation or cytotoxic chemotherapy associated with a febrile neutropenia. - autologous mobilization of peripheral blood progenitor cells. as an adjunct to allogenic mobilization of peripheral blood progenitor cells (pbpcs).